NOK 2.49
(3.11%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 7.16 Million NOK | 0.0% |
2022 | - NOK | -100.0% |
2021 | 442.43 Million NOK | 1.91% |
2020 | 434.16 Million NOK | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 6550.00 NOK | 0.0% |
2024 Q2 | 6550.00 NOK | 0.0% |
2023 Q1 | - NOK | 0.0% |
2023 FY | 7.16 Million NOK | 0.0% |
2023 Q2 | - NOK | 0.0% |
2022 FY | - NOK | -100.0% |
2021 FY | 442.43 Million NOK | 1.91% |
2020 FY | 434.16 Million NOK | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Arctic Bioscience AS | -5730.00 NOK | 125073.822% |
Aqua Bio Technology ASA | 18.46 Million NOK | 61.219% |
ArcticZymes Technologies ASA | 97.26 Million NOK | 92.638% |
BerGenBio ASA | 192.17 Million NOK | 96.274% |
Hofseth BioCare ASA | 156.04 Million NOK | 95.411% |
PCI Biotech Holding ASA | 25.23 Million NOK | 71.618% |
Ultimovacs ASA | 215.73 Million NOK | 96.681% |